Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia

This single-arm, open-label, phase 1b study evaluated the maximum tolerated dose (MTD) of venetoclax when given with obinutuzumab and its safety and tolerability in patients with relapsed/refractory (R/R) or previously untreated (first line [1L]) chronic lymphocytic leukemia (CLL). Venetoclax dose i...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Blood
Autors principals: Flinn, Ian W., Gribben, John G., Dyer, Martin J. S., Wierda, William, Maris, Michael B., Furman, Richard R., Hillmen, Peter, Rogers, Kerry A., Iyer, Swaminathan Padmanabhan, Quillet-Mary, Anne, Ysebaert, Loic, Walter, Harriet S., Verdugo, Maria, Klein, Christian, Huang, Huang, Jiang, Yanwen, Lozanski, Gerard, Pignataro, Daniela Soriano, Humphrey, Kathryn, Mobasher, Mehrdad, Kipps, Thomas J.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2019
Matèries:
Lymphoid Neoplasia
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6706803/
https://ncbi.nlm.nih.gov/pubmed/30862645
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2019-01-896290
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars